BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Lebovits Chaim reported acquisition or exercise transactions in this Form 4 filing.

BrainStorm Cell Therapeutics President & CEO Chaim Lebovits reported an award of 1,800,000 shares of common stock in the form of restricted stock units under the company’s equity plan. The RSUs vest 50% on the February 26, 2026 grant date and 50% on the six‑month anniversary, contingent on his continued employment. Following this compensation grant, he holds 2,000,960 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lebovits Chaim

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,800,000	$0.00	--

Holdings After Transaction: Common Stock — 2,000,960 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 1,800,000 shares Grant price: $0.0000 per share Post-grant holdings: 2,000,960 shares +2 more

5 metrics

RSU grant size 1,800,000 shares Restricted stock units awarded to CEO on February 26, 2026

Grant price $0.0000 per share Stated price for RSU acquisition

Post-grant holdings 2,000,960 shares Common stock directly held by CEO after RSU award

Immediate vesting portion 50% of award Vests on February 26, 2026 grant date

Deferred vesting portion 50% of award Vests on six-month anniversary of grant, subject to employment

Key Terms

restricted stock units ("RSUs"), vest, Grant, award, or other acquisition, Plan

4 terms

restricted stock units ("RSUs") financial

"Represents shares of restricted stock units ("RSUs") awarded under the Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Grant, award, or other acquisition regulatory

"transaction_code_description": "Grant, award, or other acquisition""

Plan financial

"RSUs awarded under the Plan. The RSUs shall vest as to (i) 50% of the award"

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 05:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lebovits Chaim

(Last)

(First)

(Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		1,800,000⁽¹⁾	A	$0.00	2,000,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Chaim Lebovits	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BCLI CEO Chaim Lebovits report on this Form 4?

Chaim Lebovits reported receiving 1,800,000 shares of common stock as restricted stock units under BrainStorm Cell Therapeutics’ equity plan. This is a compensation-related grant, not an open-market purchase or sale, and carries a zero dollar grant price per share.

How do the new restricted stock units for BCLI’s CEO vest?

The restricted stock units vest in two equal tranches tied to time and service. Fifty percent of the 1,800,000-unit award vests on the February 26, 2026 grant date, and the remaining 50% vests six months later, if he remains employed through each vesting date.

How many BCLI shares does the CEO hold after this RSU grant?

After the award, Chaim Lebovits is reported as holding 2,000,960 shares of BrainStorm Cell Therapeutics common stock directly. This figure reflects his position following the 1,800,000-share restricted stock unit grant disclosed in the Form 4 filing.

What does transaction code "A" mean in the BCLI CEO’s Form 4?

Transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of securities. In this case, it reflects restricted stock units of BrainStorm Cell Therapeutics granted to CEO Chaim Lebovits as equity compensation rather than a market transaction.

Is the BCLI CEO’s RSU grant an open-market stock purchase or sale?

No, the reported transaction is not an open-market trade. It is a grant of 1,800,000 restricted stock units at a stated price of $0.0000 per share, awarded under BrainStorm Cell Therapeutics’ equity plan as part of the CEO’s compensation package.